<DOC>
	<DOCNO>NCT02276209</DOCNO>
	<brief_summary>This randomize , double blind , multicenter , parallel group , outpatient study evaluate efficacy safety dasotraline adult ADHD .</brief_summary>
	<brief_title>Dasotraline Adult ADHD Study</brief_title>
	<detailed_description>This randomize , double blind , multicenter , parallel group , outpatient study evaluate efficacy safety dasotraline adult ADHD use 2 dos dasotraline ( 4 mg/day 6 mg/day ) versus placebo 8 week treatment period ( 8 week active treatment follow 2-week withdrawal phase ) .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Subject male female , 18 55 year old , inclusive , time informed consent . Diagnostic Statistical Manual Mental Disorders Fifth Edition ( DSM 5 ) criterion primary diagnosis ADHD ( inattentive , hyperactive , combine subtype ) establish comprehensive psychiatric evaluation review psychiatric criterion . Diagnosis confirm Adult ADHD Clinical Diagnostic Scale ( ACDS ) . Note : The diagnosis ADHD appropriateness inclusion trial independently confirm external expert review . Experts review diagnostic screening instrument subject approval require subject randomize . The Mini International Neuropsychiatric Interview ( MINI ) administer confirm absence comorbid psychiatric disorder . Subject ADHD RS IV adult prompt total score ≥ 26 screen Baseline . Subject CGI S score ≥ 4 screen Baseline . Subject negative breath alcohol test negative urine drug screen ( UDS ) illicit drug screening . If subject positive drug screen ADHD medication ( eg , amphetamine ) screening , subject must negative repeat UDS least 7 day baseline . Subject male non pregnant , non lactate female . Female subject must negative serum pregnancy test screening ; females post menopausal ( define least 12 month spontaneous amenorrhea ) undergone hysterectomy bilateral oophorectomy exempt pregnancy test . Female subject childbearing potential male subject female partner childbearing potential must agree use effective medically acceptable form birth control , define Section 10.4 , throughout study period . Note : Continued use effective medically acceptable form birth control recommend 30 day study completion . Subject must stable living arrangement allow consistent participation full duration study . Subject must able comply study medication administration adhere protocol requirement . Subject read well enough understand informed consent form subject material . Subjects must complete practice trial TASS assessment one timepoint Screening . Subject ≥ 25 % improvement ADHD RS IV total score screen baseline . Subject psychiatric disorder ADHD primary focus treatment time 12 month screen . Subject past history , current presentation consistent , bipolar disorder ( include bipolar I bipolar II ) , schizophrenia , schizoaffective disorder , psychotic disorder ; personality disorder per DSM 5 criterion . Subject history drug dependence Substance Related Disorder ( exclude nicotine caffeine ) within 12 month screen , define DSM 5 criterion . Subject Hamilton Anxiety Rating Scale ( HAM A ) total score ≥ 21 screen baseline . Subject PSQI total score ≥ 8 screen baseline moderate severe insomnia determine Investigator . Subject history nonresponse ( per clinician judgment ) two adequate treatment regimen stimulant nonstimulant treatment ADHD . Subject history epilepsy , seizure ( except childhood febrile seizure ) , unexplained syncope unexplained blackout ( except single incident ) , head trauma loss consciousness last 5 minute , history clinically significant multiple head trauma without loss consciousness . Subject acute chronic medical condition ( ADHD ) opinion investigator could confound clinical assessment interfere ability subject participate study . Subject currently take take within 6 week prior screen antidepressent medication ; antipsychotic medication ; lithium ( lithium preparation formulation ) . Subject currently take take within previous 6 month anticonvulsant medication ( eg , phenytoin , carbamazepine , lamotrigine , valproic acid ) ; antipsychotic medication ; lithium ( lithium preparation formulation ) . Subject currently take alpha 2 adrenergic receptor agonist ( include clonidine guanfacine ) . Subject lifetime history pattern abuse diversion stimulant . Subject body mass index ( BMI ) less 18 great 35 kg/m2 screen baseline . Subject answer `` yes '' `` suicidal ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) C SSRS assessment screening ( past month ) . Subjects answer `` yes '' question must refer Investigator follow evaluation . Subject attempt suicide within 2 year screening period . Subject history positive test Hepatitis B surface antigen Hepatitis C antibody liver function test result screen upper limit normal ( ULN ) reference laboratory . Subject know tested positive human immunodeficiency virus ( HIV ) . Subject clinically significant abnormality screen evaluation include physical examination , vital sign , ECG , laboratory test Investigator considers inappropriate allow participation study . The subject 's screening ECG show correct QT interval use Fridericia 's formula ( QTcF ) ≥ 450 msec male subject ≥ 470 msec female subject . Eligibility base core laboratory ECG interpretation report . The subject 's screening hematology result show alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value ≥ 2 time ULN , blood urea nitrogen ( BUN ) value ≥ 1.5 time ULN reference range . Subject history allergic reaction know suspected sensitivity substance contain study medication formulation . Subject currently participate participate clinical trial within last 90 day participate 2 clinical trial within past year . This include study use marketed compound device . Note : Subjects check multiple study enrollment site staff . Subject incarcerated prison within 12 month prior Screening . Subject previously randomize clinical trial dasotraline . Subject investigational site staff member relative investigational site staff member .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>